...
首页> 外文期刊>Journal of Translational Medicine >Data-driven translational prostate cancer research: from biomarker discovery to clinical decision
【24h】

Data-driven translational prostate cancer research: from biomarker discovery to clinical decision

机译:数据驱动的翻译前列腺癌研究:从生物标志物发现到临床决策

获取原文

摘要

Prostate cancer (PCa) is a common malignant tumor with increasing incidence and high heterogeneity among males worldwide. In the era of big data and artificial intelligence, the paradigm of biomarker discovery is shifting from traditional experimental and small data-based identification toward big data-driven and systems-level screening. Complex interactions between genetic factors and environmental effects provide opportunities for systems modeling of PCa genesis and evolution. We hereby review the current research frontiers in informatics for PCa clinical translation. First, the heterogeneity and complexity in PCa development and clinical theranostics are introduced to raise the concern for PCa systems biology studies. Then biomarkers and risk factors ranging from molecular alternations to clinical phenotype and lifestyle changes are explicated for PCa personalized management. Methodologies and applications for multi-dimensional data integration and computational modeling are discussed. The future perspectives and challenges for PCa systems medicine and holistic healthcare are finally provided.
机译:前列腺癌(PCA)是一种常见的恶性肿瘤,在全世界雄性中具有较高的发病率和高异质性。在大数据和人工智能的时代,生物标志物发现的范式从传统的实验和基于小数据的识别转变为大数据驱动和系统级筛选。遗传因素与环境效应之间的复杂相互作用为PCA成因和进化的系统建模提供了机会。我们在此审查了PCA临床翻译中信息学中的当前研究前沿。首先,引入了PCA开发和临床治疗方法的异质性和复杂性,以提高PCA系统生物学研究的关注。然后,对PCA个性化管理的分子交替与临床表型和生活方式改变的危险因素进行了分子和危险因素。讨论了用于多维数据集成和计算建模的方法和应用。最终提供了PCA系统医学和整体医疗保健的未来观点和挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号